Abstract
Lack of rapid and comprehensive microbiological diagnosis in patients with community acquired pneumonia (CAP) hampers appropriate antimicrobial therapy. This study evaluates the real-world performance of the BioFire FilmArray Pneumonia panel plus (FAP plus) and explores the feasibility of evaluation in a randomised controlled trial. Patients presenting to hospital with suspected CAP were recruited in a prospective feasibility study. An induced sputum or an endotracheal aspirate was obtained from all participants. The FAP plus turnaround time (TAT) and microbiological yield were compared with standard diagnostic methods (SDs). 96/104 (92%) enrolled patients had a respiratory tract infection (RTI); 72 CAP and 24 other RTIs. Median TAT was shorter for the FAP plus, compared with in-house PCR (2.6 vs 24.1 h, p < 0.001) and sputum cultures (2.6 vs 57.5 h, p < 0.001). The total microbiological yield by the FAP plus was higher compared to SDs (91% (162/179) vs 55% (99/179), p < 0.0001). Haemophilus influenzae, Streptococcus pneumoniae and influenza A virus were the most frequent pathogens. In conclusion, molecular panel testing in adults with CAP was associated with a significant reduction in time to actionable results and increased microbiological yield. The impact on antibiotic use and patient outcome should be assessed in randomised controlled trials.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 326 |
Tidsskrift | Scientific Reports |
Vol/bind | 12 |
ISSN | 2045-2322 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:C. H. van Werkhoven has received non-financial and financial research support from BioMérieux. Tristan W. Clark has received consulting fees, honoraria for lectures and manuscript writing/educational events, support for attending meetings and other services from BioMérieux and BioFire LLC. The other authors have nothing to disclose.
Funding Information:
This work was supported by the Trond Mohn Foundation (RESPNOR; BFS2019TMT06), The Research Council of Norway (NORCAP; 288718), The University of Bergen and Haukeland University Hospital.
Publisher Copyright:
© 2022, The Author(s).